MX2010005683A - Conjugados de anticuerpos anti-rg-1. - Google Patents

Conjugados de anticuerpos anti-rg-1.

Info

Publication number
MX2010005683A
MX2010005683A MX2010005683A MX2010005683A MX2010005683A MX 2010005683 A MX2010005683 A MX 2010005683A MX 2010005683 A MX2010005683 A MX 2010005683A MX 2010005683 A MX2010005683 A MX 2010005683A MX 2010005683 A MX2010005683 A MX 2010005683A
Authority
MX
Mexico
Prior art keywords
antibodies
conjugates
partner
cytotoxins
internalized
Prior art date
Application number
MX2010005683A
Other languages
English (en)
Spanish (es)
Inventor
David J King
Josephine M Cardarelli
Chin Pan
Jonathan A Terrett
Sanjeev Gangwar
Chetana Rao-Naik
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40427118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010005683(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2010005683A publication Critical patent/MX2010005683A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
MX2010005683A 2007-11-30 2008-11-26 Conjugados de anticuerpos anti-rg-1. MX2010005683A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99169007P 2007-11-30 2007-11-30
PCT/US2008/084899 WO2009073524A2 (en) 2007-11-30 2008-11-26 Conjugates of anti-rg-1 antibodies

Publications (1)

Publication Number Publication Date
MX2010005683A true MX2010005683A (es) 2010-06-11

Family

ID=40427118

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005683A MX2010005683A (es) 2007-11-30 2008-11-26 Conjugados de anticuerpos anti-rg-1.

Country Status (18)

Country Link
US (1) US20110020329A1 (enExample)
EP (1) EP2211908A2 (enExample)
JP (1) JP2011505371A (enExample)
KR (1) KR20100101122A (enExample)
CN (1) CN101951960A (enExample)
AR (1) AR069746A1 (enExample)
AU (1) AU2008331507A1 (enExample)
BR (1) BRPI0819765A2 (enExample)
CA (1) CA2707443A1 (enExample)
CL (1) CL2008003525A1 (enExample)
CO (1) CO6210734A2 (enExample)
EA (1) EA201000921A1 (enExample)
IL (1) IL206060A0 (enExample)
MX (1) MX2010005683A (enExample)
NZ (1) NZ586514A (enExample)
TW (1) TW200930407A (enExample)
WO (1) WO2009073524A2 (enExample)
ZA (1) ZA201003729B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518403B2 (en) * 2004-07-16 2013-08-27 Amgen Research (Munich) Gmbh Expression-enhanced polypeptides
RU2628069C2 (ru) 2008-11-03 2017-08-14 Синтарга Б.В. Новые аналоги сс-1065 и их конъюгаты
LT3108886T (lt) 2010-04-21 2020-08-25 Syntarga B.V. Cc-1065 analogų ir bifunkcinių jungtukų konjugatai
EP2576621B1 (en) 2010-05-27 2019-04-10 Genmab A/S Monoclonal antibodies against her2
CN103153339B (zh) * 2010-05-27 2021-05-04 根马布股份公司 针对her2表位的单克隆抗体
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
TR201810856T4 (tr) 2014-01-10 2018-08-27 Synthon Biopharmaceuticals Bv CYS'le bağlı antikor-ilaç konjugatlarını saflaştırmak için usul.
JP2017510548A (ja) * 2014-01-29 2017-04-13 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． リガンド‐細胞傷害性薬物抱合体、その製造方法、およびその用途
IL316357A (en) * 2017-07-31 2024-12-01 Trishula Therapeutics Inc Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912227A (en) * 1984-02-21 1990-03-27 The Upjohn Company 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds
US4978757A (en) * 1984-02-21 1990-12-18 The Upjohn Company 1,2,8,8a-tetrahydrocyclopropa (C) pyrrolo [3,2-e)]-indol-4(5H)-ones and related compounds
US5332837A (en) * 1986-12-19 1994-07-26 The Upjohn Company CC-1065 analogs
US5084468A (en) * 1988-08-11 1992-01-28 Kyowa Hakko Kogyo Co., Ltd. Dc-88a derivatives
JP2598116B2 (ja) * 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
JP2510335B2 (ja) * 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
US5187186A (en) * 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
AU648313B2 (en) * 1990-04-25 1994-04-21 Pharmacia & Upjohn Company Novel CC-1065 analogs
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
PT705833E (pt) * 1994-04-22 2004-11-30 Kyowa Hakko Kogyo Kk Derivado de dc-89
JPH07309761A (ja) * 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd デュオカルマイシン誘導体の安定化法
US5871969A (en) * 1996-02-12 1999-02-16 Human Genome Sciences, Inc. Nucleic acids encoding human neuronal attachment factor-1
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
CA2448319C (en) * 2001-05-31 2010-07-27 Medarex, Inc. Cytotoxins, prodrugs, linkers and stabilizers useful therefor
JP2005502703A (ja) * 2001-09-07 2005-01-27 ザ スクリプス リサーチ インスティテュート Ｃｃ−１０６５およびデュオカルマイシンのｃｂｉ類似体
US7091186B2 (en) * 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
UY28424A1 (es) * 2003-07-22 2005-02-28 Schering Ag Anticuerpos rgi y usos de los mismos.
AU2005244980B2 (en) * 2004-05-19 2011-09-15 E. R. Squibb & Sons, L.L.C. Chemical linkers and conjugates thereof
RU2402548C2 (ru) * 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
ES2416136T3 (es) * 2005-09-26 2013-07-30 Medarex, Inc. Conjugados de anticuerpo-fármaco y su uso
WO2007059404A2 (en) * 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
JP5189082B2 (ja) * 2006-05-25 2013-04-24 バイエル・ファルマ・アクチェンゲゼルシャフト 二量体分子複合体

Also Published As

Publication number Publication date
ZA201003729B (en) 2011-08-31
AR069746A1 (es) 2010-02-17
BRPI0819765A2 (pt) 2015-05-05
TW200930407A (en) 2009-07-16
EA201000921A1 (ru) 2010-12-30
CL2008003525A1 (es) 2010-01-22
CN101951960A (zh) 2011-01-19
KR20100101122A (ko) 2010-09-16
IL206060A0 (en) 2010-11-30
AU2008331507A1 (en) 2009-06-11
WO2009073524A2 (en) 2009-06-11
EP2211908A2 (en) 2010-08-04
WO2009073524A3 (en) 2009-12-10
CA2707443A1 (en) 2009-06-11
CO6210734A2 (es) 2010-10-20
JP2011505371A (ja) 2011-02-24
NZ586514A (en) 2012-05-25
US20110020329A1 (en) 2011-01-27

Similar Documents

Publication Publication Date Title
MX2010005683A (es) Conjugados de anticuerpos anti-rg-1.
UA111341C2 (uk) Аматоксиновий кон'югат з покращеними лінкерами
MX2010005830A (es) Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
EA200800952A1 (ru) Конъюгаты антитело-лекарство и способы применения
MY148231A (en) Leptomycin derivatives
MX2009006277A (es) Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
WO2006124737A3 (en) Molecular constructs suitable for targeted conjugates
WO2005117986A3 (en) Antibody drug conjugates and methods
EP2408470A4 (en) SOLUBLE NONDEPOT INSULIN CONJUGATE AND ITS USE
WO2007105027A8 (en) Anticancer drugs conjugated to antibody via an enzyme cleavable linker
WO2010115629A3 (en) Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
NO20083891L (no) Anti-5T4 antistoffer og anvendelser derav
GEP20196956B (en) Anti-gcc antibody molecules and related compositions and methods
AR064109A1 (es) Anticuerpos humanos que se enlazan al cd22 y sus usos
IN2012DN04908A (enExample)
MX2010009670A (es) Conjugados de paclitaxel polimericos y metodos para tratamiento de cancer.
TN2014000148A1 (en) Antigen binding protein and its use as addressing product for the treatment of cancer
MY145058A (en) Prlr-specific antibody and uses thereof
UA110370C2 (en) Conjugates of amatoxin with improved linkages
EP1844077A4 (en) DR5 ANTIBODIES AND THEIR USE
BRPI0910746B8 (pt) agente de reticulação, conjugado de agente de ligação celular-fármaco, seu uso, composto e composição farmacêutica
BR112012024564A2 (pt) anticorpos contra csf-1r
MX2009002820A (es) Conjugados polimericos de box-a de hmgb1 y variantes de box-a de hmgb1.
MX2009001341A (es) Anticuerpos especificos de ephb3 y usos de los mismos.
MX2023014683A (es) Conjugados de anticuerpo anti-egfrviii y farmaco y usos de los mismos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal